ISPOR 15th Annual European Congress Banner
Program: Tuesday, 6 November 2012
7:30 - 8:30
EDUCATIONAL SYMPOSIUM (Sponsored by EFPIA)
The Impact of European Collaboration on NATIONAL Relative Effectiveness Assessment
8:45 - 13:45
RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III
8:45 - 9:45
RESEARCH PODIUM PRESENTATIONS – SESSION III
8:45 - 9:45

CANCER OUTCOMES RESEARCH

CA1

DISCORDANT DIAGNOSES IN SARCOMA, GIST AND DESMOIDE TUMOUR IN FRANCE: RESULTS FROM THE NETWORK RREPS

 

Perrier L1, Ranchère Vince D1, Terrier P2, Neuville A3, Decouvelaere AV1, Bui B3, Le Cesne A2, Ray Coquard I1, Ducimetière F1, Jean-Denis M1, Courrèges JB3, Mesli N2, Morelle M1, Plommet N4, Blay JY1, Coindre JM3
1Leon Berard Cancer Centre, Lyon, France, 2Insitut Gustave Roussy, Villejuif, France, 3Institut Bergonié, Bordeaux, France, 4University Lyon 2, Lyon, France

8:45 - 9:45

CA2

APPLYING A VALUE-BASED PRICE ACROSS DIFFERENT DISEASE AREAS

 

Wilson T, Kusel J, Brooks-Rooney C, Costello S
Costello Medical Consulting Ltd., Cambridge, UK

8:45 - 9:45

CA3

USE OF HEALTH CARE ADMINISTRATIVE DATABASES TO ESTIMATE THE BURDEN OF BREAST CANCER

 

Ciampichini R1, Furneri G1, Scalone L2, Cortesi PA2, Fornari C2, Madotto F2, Chiodini V2, Mantovani LG3, Cesana G2
1Charta Foundation, Milan, Italy, 2University of Milano-Bicocca, Monza, Italy, 3Federico II University of Naples, Naples , Italy

8:45 - 9:45

CA4

A COMPARISON OF PATIENT AND GENERAL-POPULATION UTILITY VALUES FOR ADVANCED MELANOMA IN HEALTH ECONOMIC MODELLING

 

Batty A1, Winn B1, Lebmeier M2, Rowen D3, Lee D1
1BresMed, Sheffield, UK, 2Bristol-Myers Squibb Company, Uxbridge, Middlesex, UK, 3University of Sheffield, Sheffield, South Yorkshire, UK

8:45 - 9:45

CLINICAL OUTCOMES STUDY METHODOLOGICAL CHALLENGES

CL1

A MULTICRITERIA APPROACH FOR EVALUATING HEALTH-RELATED QUALITY-OF-LIFE

 

Manolitzas P1, Krasoudakis A2, Grigoroudis E1, Matsatsinis N1, Archontakis G2
1Technical University of Crete, Chania, Greece, 2General Hospital of Chania, Crete, Greece

8:45 - 9:45

CL2

STATISTICAL CONSIDERATIONS IN ESTIMATING SURVIVAL FOR ECONOMIC EVALUATIONS IN ONCOLOGY

 

Khan N1, Shah D1, Briggs A2, Park J3, Huang H4, Hawkins N5
1Oxford Outcomes Ltd., Morristown, NJ, USA, 2University of Glasgow, Glasgow, UK, 3Millennium Pharmaceuticals, Inc., Boston, MA, USA, 4Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, 5Oxford Outcomes, Oxford, UK

8:45 - 9:45

CL3

CALIBRATING BAYESIAN MULTIPLE TREATMENT COMPARISON META-ANALYSIS WITH MULTIPLE COST-EFFECTIVENESS ACCEPTABILITY CURVES

 

Thorlund K1, Mills E2
1McMaster University, Hamilton, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada

8:45 - 9:45

CL4

MARGINAL STRUCTURAL MODELS USED IN ESTIMATING COST-EFFECTIVENESS OF TIME-VARYING DRUG THERAPY USING ADIMISTRATIVE DATABASES. THE CASE OF STATIN IN SECONDARY PREVENTION

 

Fornari C1, Valsecchi MG1, Galimberti S1, Madotto F1, Conti S1, Mantovani LG2, Cesana G1
1University of Milano-Bicocca, Monza, Italy, 2Federico II University of Naples, Naples, Italy

8:45 - 9:45

DRUG USE RESEARCH TO INFORM POLICY DECISION MAKING

DU1

A TIME SERIES ANALYSIS OF THE EFFECT OF THE CO-PAYMENT ON PHARMACEUTICAL CONSUMPTION IN TWO ITALIAN REGIONS

 

Siviero PD1, Cangini A1, Fabrizi E2
1Italian Medicines Agency (AIFA), Rome, Italy, 2University of Teramo and IMS Health, Teramo, Italy

8:45 - 9:45

DU2

CONTRIBUTION OF PROLONGED-RELEASE MELATONIN AND ANTI-BENZODIAZEPINE CAMPAIGNS TO THE REDUCTION OF BENZODIAZEPINE AND Z-DRUG CONSUMPTION IN NINE EUROPEAN COUNTRIES

 

Clay E1, Falissard B2, Moore N3, Toumi M4
1Creativ-Ceutical, Paris, France, 2INSERM U-669 PSIGIAM, Paris, France, 3University of Bordeaux, Bordeaux, France, 4University Claude Bernard Lyon 1, Lyon, France

8:45 - 9:45

DU3

MARKET ACCESS DELAYS FOR CNS DRUGS IN EUROPE

 

Flostrand SJA1, Anderson L2, Esposito G3
1IMS Consulting Group, Puteaux, France, 2IMS Consulting Group, London, UK, 3H. Lundbeck A/S, Copenhagen, Denmark

8:45 - 9:45

DU4

INAPPROPRIATE USE OF DRUGS INFLUENCES HEALTH BUDGET OF POPULATION

 

Sabo A, Tomic Z, Calasan J, Milijasevic B, Vukmirovic S
Medical University Novi Sad, Novi Sad, Serbia and Montenegro

8:45 - 9:45

DRIVERS OF REIMBURSEMENT TECHNOLOGY

RE1

FACTORS INFLUENCING DRUG REIMBURSEMENT DECISION IN SCOTLAND

 

Charokopou M, Heeg B, Majer IM
Pharmerit International, Rotterdam, Zuid-Holland, The Netherlands

8:45 - 9:45

RE2

A DETAILED COMPARISON OF DUTCH AND SWEDISH DRUG REIMBURSEMENT DECISIONS: WHAT EVIDENCE IS AVAILABLE, WHICH CRITERIA ARE USED, AND IS THE DECISION-MAKING PROCESS TRANSPARENT?

 

Franken MG1, Nilsson F2, Sandmann F1, de Boer A3, Koopmanschap MA1
1Erasmus University, Rotterdam, The Netherlands, 2Dental and Pharmaceutical Benefits Agency, Solna, Sweden, 3Utrecht University, Utrecht, The Netherlands

8:45 - 9:45

RE3

HOW WILL THE NEW NHS CHANGES IN ENGLAND IMPACT THE IMPLEMENTATION OF RISK SHARING SCHEMES FOR ONCOLOGY TREATMENTS?

 

Jeffery M, Assimakopoulos M, White R
Access Partnership, London, UK

8:45 - 9:45

RE4

BEYOND THE EVIDENCE - THE INFLUENCE OF DECISION PROCESSES ON OUTCOMES IN COVERAGE DETERMINATION OF HEALTH TECHNOLOGIES

 

Fischer KE1, Rogowski WH2, Leidl R2, Stollenwerk B2
1University of Hamburg, Hamburg, Germany, 2Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany

8:45 - 9:45

VACCINE RESEARCH

VA1

A EUROPEAN-WIDE STUDY ON THE ROLE OF STREPTOCOCCUS PNEUMONIAE IN COMMUNITY-ACQUIRED PNEUMONIA AMONG ADULTS: A META-ANALYSIS

 

Pechlivanoglou P1, Rozenbaum M1, van der Werf T2, Lo-Ten-Foe J2, Postma M1, Hak E1
1University of Groningen, Groningen, The Netherlands, 2University Medical Center Groningen, Groningen, The Netherlands

8:45 - 9:45

VA2

CORRELATES OF PROTECTION FOR VACCINES: WHEN DOES A CORRELATE EQUAL PROTECTION?

 

Desai K1, Chen X2, Bailleux F3, Qin L4, Dunning A5
1United BioSource Corporation, London, UK, 2Sanofi Pasteur, Beijing, China, 3Sanofi Pasteur, Marcy-l'Étoile, France, 4University of Washington, Seattle, WA, USA, 5Sanofi Pasteur, Swiftwater, PA, USA

8:45 - 9:45

VA3

HOW AGENT-BASED MODELS REVEAL THE DYNAMIC OF EPIDEMICS – A CASE STUDY ON INFLUENZA

 

Miksch F1, Urach C1, Zauner G2, Schiller-Frühwirth I3, Endel G3, Einzinger P2, Popper N2
1Vienna University of Technology, Vienna, Austria, 2Dwh Simulation Services, Vienna, Austria, 3Main Association of Austrian Social Security Institutions, Vienna, Austria

8:45 - 9:45

VA4

FOUND THE MISSING LINK? HOW TO RELATE COHORT MODELS TO OBSERVED POPULATION DATA

 

Standaert B1, Ethgen O2, Emerson RA3
1GlaxoSmithKline Vaccines, Wavre, Belgium, 2University of Liege, Liege, Belgium, 3Emerson Consulting, Tervuren, Belgium

9:45 - 10:15
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III
10:15 - 11:30
WELCOME & SECOND PLENARY SESSION
WELCOME
Deborah Marshall, PhD, MHSA

Deborah Marshall, PhD, MHSA
2012-2013 ISPOR President and Associate Professor, University of Calgary and University of McMaster, Director, HTA, Alberta Bone and Joint Health Institute & Canada Research Chair, Health Services and Systems Research Centers, Calgary, AB, Canada

 
Policy measures such as international referencing (using other countries as a benchmark) to set drug prices and internal reference pricing systems to promote price competition in domestic markets are quite common in Europe.  The process for referencing varies considerably and not all health systems make their formula for calculating the reference price explicit.  In some countries, the rules for referencing can only be figured out empirically by their respective decisions.  The choice of reference country, which can be a subject of public debate (e.g. in Germany where some elements of reference pricing were recently introduced) will also determine, to a large extent, the reference price. It is therefore difficult for the pharmaceutical industry to model the outcome of this process, as the different referencing activities in various national pharmaceutical markets interact. This session will provide an overview of current practices within European markets.  Reasons for international price differentiation, common policy patterns in this field and current trends in the methods to compare prices on an international level will be discussed.
Andrew Jack Moderator:
Andrew Jack
Pharmaceuticals Correspondent, Financial Times, London, UK
Kees de Joncheere, PharmD, MBA, MSc Speakers:
Kees de Joncheere, PharmD, MBA, MSc
Director, Department of Essential Medicines and Health Products, World Health Organization (WHO), Geneva, Switzerland
Thomas B. Cueni

Thomas B. Cueni, MSc
Secretary General, Interpharma, Basel, Switzerland

Ulrich Kaiser, PhD, MSc Ulrich Kaiser, PhD, MSc
Professor, Department of Business Administration – Entrepreneurship, University of Zürich, Zürich, Switzerland
11:30 - 13:45
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION III
11:45 - 12:45
EDUCATIONAL SYMPOSIUM (Sponsored by RTI)
EFFECTIVE COMMUNICATION WITH FEDERAL AUTHORITIES FOR SCIENTIFIC ADVICE EARLY IN PRODUCT DEVELOPMENT
12:45 - 13:45
POSTER AUTHOR DISCUSSION HOUR – SESSION III
13:45 - 14:45
Research Poster Presentations Hall Closed
13:45 - 14:45
ISSUE PANELS – SESSION II
13:45 - 14:45
IP6: REWARDING THE VALUE ADDED BY NEW DRUGS: WHICH OF TWO EUROPEAN APPROACHES IS SUPERIOR?
Moderator: Matthias Graf von der Schulenburg, PhD, Director, Institute for Risk and Insurance, Leibniz University, Hannover, Germany
Panelists: Elizabeth C Jones, MSc, Senior Research Analyst, HEOR, OptumInsight, Uxbridge, UK; Gerard de Pouvourville, PhD, Professor, Department of Health Care Management and Chair, Health Economics Institute, ESSEC Business School, Cergy Pontoise, France; Michael Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York and Principal Consultant, OptumInsight, Heslington, York, UK
13:45 - 14:45
IP7: SHOULD MULTIPLE CRITERIA DECISION ANALYSIS (MCDA) REPLACE COST-EFFECTIVE ANALYSIS (CEA)?
Moderator:

J. Jaime Caro, MDCM, FRCPC, FACP, Senior Vice President, Research, United BioSource Corporation, Lexington, MA, USA

Panelists: Karl Claxton, PhD, Professor of Economics, Centre for Health Economics, University of York, Heslington, York, UK; Andreas Gerber, PhD, MD, Head, Department of Health Economics, Institute of Quality and Efficiency in Health Care (IQWiG), Cologne, Germany; Warren Cowell, MSc, HTA Policy, Pfizer, Tadworth, Surrey, UK
13:45 - 14:45
IP8: HOW DO YOU ASSESS THE VALUE OF CO-DEPENDENT TECHNOLOGIES?
Moderator: Adrian Towse, MA, MPhil, Director, Office of Health Economics, London, UK
Panelists: Martina Garau, BA, (HONS), MSc, Senior Economist, Office of Health Economics, London, UK; Diego F. Ossa, MD, MSc, Global Head, HEOR MDx, Novartis Pharma AG, Basel, Switzerland; Mira Pavlovic-Ganascia, MD, Deputy Director for Health Technology Assessment at the Haute Autorité de Santé (HAS), La Plaine Saint Denis, France
13:45 - 14:45
IP9: EVIDENCE GENERATION VIA CONDITIONAL COVERAGE FOR MEDICAL TECHNOLOGIES - WHAT KIND OF EVIDENCE SHOULD BE GENERATED TO SUPPORT ACCESS TO RELEVANT INNOVATIONS?
Moderator: Bernd H. Brüggenjürgen, MD, MPH, Head, Institute for Health Economics, Steinbeis University Berlin and Vice Chairman, German Association for Health Sciences and Public Health, Berlin, Germany
Panelists: Pippa Anderson, BSc, MSc, Managing Director, Swansea Centre for Health Economics, Swansea University, Swansea, UK; Joseph V. Ferrara, MA, President, Boston Healthcare Associates, Inc., Boston, MA, USA; Annie Chicoye, PhD, Executive Director for Development, Health Management Institute, ESSEC Business School Paris-Singapore, Cergy-Pontoise, France
13:45 - 14:45
IP10: WHICH TO USE? POPULATION BASED OR INDIVIDUAL PATIENT ASSESSMENTS OF VALUE
Moderator: Stephen James Furniss, BA, Senior Vice President, Market Access, GfK Bridgehead, Melton Mowbray, Leicestershire, UK
Panelists: Ron Akehurst, BSc, Professor of Health Economics, Dean of School of Health & Related Research (ScHARR), University of Sheffield, Sheffield, UK; Sue Kilby, MSc, MBA, BPharm, Network Pharmacist South West London Cancer Network, London, UK
14:45 - 15:00
BREAK & EXHIBITS VIEWING
15:00 - 19:00
RESEARCH POSTER PRESENTATIONS VIEWING – SESSION IV
15:00 - 16:00
WORKSHOPS – SESSION II
15:00 - 16:00
W7: INNOVATIVE USES OF PHASE III DATA TO PLAN PHASE IV RESEARCH
Discussion Leaders:

David Thompson, PhD, Senior Vice President & Head of Emerging Business, Quintiles Outcome, Cambridge, MA, USA; Sandrine Cure, MSc, Associate Director, OptumInsight, Uxbridge, Middlesex, UK; Raquel Cabo, MSc, Global Health Economics Manager, Health Economics and Reimbursement, GE Healthcare, Chalfont St. Giles, Bucks, UK

15:00 - 16:00
W8: IT'S TIME TO REASSESS TRADITIONAL TIME-DEPENDENT REGRESSION METHODS
Discussion Leaders:

Christopher M. Blanchette, PhD, Research Associate Professor, Public Health Sciences, University of North Carolina, Charlotte, NC, USA and Principal, Health Economics & Outcomes Research, IMS Health, Alexandria, VA, USA; Alex Exuzides, PhD, Director, ICON Late Phase & Outcomes Research, San Francisco, CA, USA; Roger Luo, PhD, Director, Advanced Analytics, IMS Health, Plymouth Meeting, PA, USA

15:00 - 16:00
W9: EARLY MODELLING IN MEDICAL PRODUCT DEVELOPMENT AND MARKET ACCESS
Discussion Leaders:

Maarten J. IJzerman, PhD, Professor & Chair, Department of Health Technology & Services Research, University of Twente, Enschede, The Netherlands; Mark J. Sculpher, MSc, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Pierre Sagnier, MD, DEA, MPH, Head, Global Market Access, HEOR, General Medicine, Bayer HealthCare, Berlin, Germany

15:00 - 16:00
W10: THE IMPLEMENTATION OF DISINVESTMENT INITIATIVES: A EUROPEAN PERSPECTIVE ON PROGRESS TO DATE
Discussion Leaders:

Christian A Gericke, MD, PhD, MPH, MSc, Professor and Deputy Director, PenCLAHRC, Plymouth, Devon, UK; Sarah Garner, PhD, BPharm, Associate Director, Research and Development, National Institute of Health and Clinical Excellence (NICE), London, UK; Francois Meyer, MD, Advisor to the President and Director for International Affairs, Haute Autorité de Santé (HAS), Saint-Denis, France

15:00 - 16:00
W11: ADHERENCE AS A DIFFERENTIATING FACTOR IN THE APPRAISAL OF NEW TREATMENTS: SHOULD ECONOMIC EVALUATION CONSIDER WHETHER PATIENTS TAKE THEIR TREATMENT APPROPRIATELY?
Discussion Leaders:

Antoine Regnault, PhD, Research Director, MAPI Consultancy, Lyon, France; Gert Bergman, PhD, Associate Director, MAPI Consultancy, Houten, The Netherlands; Chloe Brown, PHD, Director, RJW & Partners, Royston, Hertfordshire, UK

15:00 - 16:00
W12: PAYER AND HTA PERSPECTIVES ON CLINICAL OUTCOME ASSESSMENTS (COAS)
Discussion Leaders:

Erin Tomaszewski, MPH, Clinical Outcomes Research Scientist, Quintiles Outcome, Pittsburgh, PA, USA; Peter Black, MS, Senior Scientist, invivodata Consulting, Pittsburgh, PA, USA; Marta Andreykiv, PharmD, MSc, Senior Consultant, Consulting, Quintiles, Hoofddorp, The Netherlands; Stefan Holmstrom, MSc, Director, HEOR, Astellas Pharma Global Development, Leiderdorp, The Netherlands

16:15 - 17:15
WORKSHOPS – SESSION III
16:15 - 17:15
W13: RETHINKING ANALYSIS OF OUTCOME MEASURES FOR DEMONSTRATING VALUE OF PHARMACEUTICAL PRODUCTS: IMPLICATIONS FOR STUDY DESIGN, PERSONALIZED MEDICINE, AND COMPARATIVE EFFECTIVENESS RESEARCH
Discussion Leaders:

Donald E. Stull, PhD, Director Retrospective Data Analysis, RTI Health Solutions, Didsbury, Manchester, UK; Katherine Houghton, BSc, Research Health Outcomes Scientist, RTI Health Solutions, Didsbury, Manchester, UK; Jennifer Petrillo, PhD, Associate Director, Global Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

16:15 - 17:15
W14: MODELING OF INFECTIOUS DISEASES FOR PREVENTION AND MITIGATION: HOW MODELING HAS INFORMED PUBLIC HEALTH POLICY
Discussion Leaders:

Maarten J. Postma, PhD, Professor, Department of Pharmacy, University of Groningen, Groningen, The Netherlands; Kamal Desai, PhD, Research Scientist, Health Economic Modeling and Simulation, United BioSource Corporation, London, UK; Deirdre Hollingsworth, PhD, Research Fellow, MRC Centre for Outbreak Analysis and Modelling, Imperial College London, London, UK; Ruth Chapman, PhD, Research Assistant, Health Economic Modelling and Simulation, United BioSource Corporation, London, UK

16:15 - 17:15
W15: WHAT IS VERSUS WHAT COULD BE: INCORPORATING OPERATIONS RESEARCH METHODS IN THE HEOR TOOLKIT
Discussion Leaders:

William Crown, PhD, Group President, HEOR and Late Phase Research, OptumInsight, Waltham, MA, USA; Deborah Marshall, PhD, MHSA, Canada Research Chair, Health Services & Systems Research, Associate Professor, Department of Community Health Sciences, Faculty of Medicine and Director, HTA, Alberta Bone & Joint Health Institute, University of Calgary, Calgary, AB, Canada

16:15 - 17:15
W16: DON'T FORGET ABOUT THE PATIENT! LISTENING TO PATIENTS AND INVOLVING THEM IN RESEARCH
Discussion Leaders:

Elisa Cascade, MBA, Vice President, MediGuard/Digital Patient Unit, Quintiles, Rockville, MD, USA; Derek C Stewart, BA, Associate Director for Patient & Public Involvement, Clinical Research Networks, National Institute for Health Research, Leeds, UK; Dean Summerfield, MA, DPhil, Vice President, Europe, Quintiles Consulting, Reading, UK

16:15 - 17:15
W17: ADDITIONAL PATIENT RELATED BENEFITS ARE THE KEY TO PRICE NEGOTIATION IN GERMANY – PRACTICAL EXPERIENCE WITH BENEFIT DOSSIERS AND THE ASSESSMENT PROCESS
Discussion Leaders:

Olaf Pirk, MD, PhD, Director, Olaf Pirk Consult, Nuremberg, Germany; Meriem Hind Bouslouk, PhD, Official Adviser, Drug Department, Federal Joint Committee (G-BA), Berlin, Germany; Frank-Ulrich Fricke, PhD, Professor, Deputy Member of the Arbitration Panel for Drugs, Georg-Simon-Ohm University of Applied Sciences, Nuremberg, Germany

16:15 - 17:15
W18: CHOICE DEFINES VALUE: NEW APPROACHES TO ESTIMATING QALYS, HYES, AND EFFICIENCY FRONTIERS
Discussion Leaders:

Benjamin M Craig, PhD, Assistant Faculty Member, Health Outcomes & Behavior, Moffitt Cancer Center, Tampa, FL, USA; Juan Marcos Gonzalez, PhD, Research Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA; Axel C. Mühlbacher, PhD, Professor for Health Economics and Health Care Management, IGM Institute, Hochschule Neubrandenburg, Neubrandenburg, Germany

17:15 - 19:00
EXHIBITORS’ WINE & CHEESE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION IV
17:30 - 18:30
ISPOR FORUMS – SESSION II
17:30 - 18:30
HEALTH EVIDENCE FOR DECISION MAKING: ASSESSMENT TOOL FOR MODELING STUDIES
A web based assessment tool for modeling studies for health care decision makers will be discussed. Presented by the ISPOR/AMCP/NPC CER-CI: Interpreting Modeling Studies for Health Care Decision Makers Task Force

Speaker: J. Jaime Caro, MDCM, FRCPC, FACP, Adjunct Professor of Medicine, Adjunct Professor of Epidemiology and Biostatistics, McGill University, Montreal PQ and Senior Vice-President, Research, United BioSource Corporation, Lexington, MA, USA
17:30 - 18:30
MIXED MODES OF PRO DATA COLLECTION: ISPOR PRO TASK FORCE FINAL RECOMMENDATIONS

This forum presentation will provide important updates regarding migration and equivalence evaluation, as well as implementation of clinical trials involving more than one mode of data collection (e.g., paper and handheld device; IVR and Web) to ensure the quality and comparability of the resulting PRO data and to review analytical approaches for evaluating and pooling mixed modes data. Presented by the ISPOR PRO Mixed Modes Task Force

Moderator/Speaker: Sonya Eremenco MA, ePRO Manager, United BioSource Corporation, Bethesda, MD, USA

Speakers: Stephen Joel Coons, PhD, MS, MEd, Director, Patient-Reported Outcomes Consortium, Critical Path Institute, Tucson, AZ, USA; Jean Paty, PhD, Chief Scientific and Regulatory Advisor - Outcomes, ERT, Inc., Pittsburgh, PA, USA

17:30 - 18:30
HTA AND REIMBURSEMENT SYSTEMS IN RUSSIA AND POLAND: COMMON PROBLEMS AND SOLUTIONS
Russia and Poland represent different paths in the development of health care systems; especially with Poland's recently adopted new law on reimbursement. This forum will discuss common challenges and solutions in the area of health technology assessment and reimbursement. Speakers will focus on non-pharmaceutical technologies, as their assessment is one of the most interesting issues in health economics. An overview of reimbursement systems and HTA in Russia and Poland will be provided. The use of HTA, risk-sharing agreements, pricing of medicines, and types of negotiation in their reimbursement systems, will be discussed. Presented by the ISPOR Poland, Russia and Russia Far-East Chapters

Moderators/Speakers: Pavel Vorobiev, MD, MSc, PhD, President, ISPOR Russia Regional Chapter, Professor, Moscow Sechenov Medical Academy and Head of the Research Department on Health Care Standardization Problems, Moscow, Russia; Karina Jahnz-Rozyk, MD, PhD, President, ISPOR Poland Regional Chapter and Head of Department of Immunology & Allergology, Military Institute of Medicine, Warsaw, Poland

Speakers: Joanna Lis, MSc, PhD, Director of Public Affairs and Market Access, Sanofi, Warsaw, Poland; Lyubov Krasnova, MD, PhD, Leading Researcher, Research Department on Health Care Standardization Problems, Moscow Sechenov Medical Academy, Moscow, Russia; Alexander V. Bykov, MD, PhD, Director, State and Social Structures, Novo Nordisk, Moscow, Russia
17:30 - 18:30
HEALTH TECHNOLOGY ASSESSMENT IN A RESOURCE CONSTRAINED SETTING: REAL CHALLENGES FACING ASIA
The global trend of HTA and the need for informed decisions have created momentum for introducing HTA into health care decision-making in Asia. However, few countries in Asia have the financial or human resources needed, and health care systems and political environments vary significantly within Asia. The challenges to establish an HTA system in Asia will be discussed. Presented by the ISPOR Asia Consortium

Moderator/Speaker: Bong-Min Yang, PhD, Professor of Economics, School of Public Health, Seoul National University, Seoul, South Korea

Speakers: Surachat Ngorsuraches PhD, RPh, Associate Professor, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkhla, Thailand; Kenneth KC Lee, BSc (Pharm), MPhil, PhD, Professor of Pharmacy and Head of Pharmacy Programme, School of Medicine and Health Sciences, Monash University, Kuala Lumpur, Malaysia; Wen Chen, PhD, Professor & Deputy Dean, School of Public Health, Fudan University, Shanghai, China
17:30 - 18:30
METHODS OF FINANCING AND DECISION MAKING IN HEALTH CARE IN CENTRAL & EASTERN EUROPE IN TIMES OF LIMITED FUNDS: REVOLUTION OR EVOLUTION?
The current economic crisis has impacted decision making processes in all fiscal sectors, including health care. Health care policy makers (health planners, sick funds & insurers, payers, health technology assessors, hospital financial management and health department officials) are under extreme budgetary pressure. How can payers make the right decision in a high-risk and highly uncertain environment without jeopardizing patient's quality of life? This forum will explain the impact of reference pricing, parallel trade and the availability of innovative technologies in some CEE countries. The implementation of diagnosis related groups (DRGs) in Greece, the role of budget impact methods in decision-making processes in Croatia, and methods of financing and decision making in pharmaceuticals in Bulgaria will be discussed. Presented by the ISPOR Bulgaria, Croatia, and Greece Chapters

Moderator: Guenka Petrova, MPharm, MEcon, PhD, DSc, President, ISPOR Bulgaria Regional Chapter and Professor, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria

Speakers: Assena Stoimenova, PhD, Associate Professor, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria; Josip Čulig, PhD, Professor of Clinical Pharmacology and Toxicology, University JJ.Strossmayer, Medical School Osijek, Osijek, Croatia; John Yfantopoulos, PhD, Professor, Health Economics, University of Athens, Athens, Greece
17:30 - 18:30
PATIENTS AND THEIR ROLE IN MARKET ACCESS: WHERE IS THE PLACE AND WHAT IS THE ROLE OF PATIENTS IN REIMBURSEMENT SYSTEMS?
Patients are important stakeholders in health care delivery and utilization of resources by paying taxes, health insurance premiums and out-of-pocket expenses. The role of patients in reimbursement systems is increasingly influencing access to drugs and other treatments. Patients Empowerment (PE) is a way to educate patients, who care about their therapies. Education is key when making patients aware of their rights and obligations related to health care utilization. This forum will discuss the importance of educating patients about health care and their role in the reimbursement systems. Examples of Romania, Serbia and Slovakia will be provided. Presented by the ISPOR Romania, Serbia and Slovakia Chapters

Moderators/Speakers: Dominik Tomek, PharmD, MPH, PhD, President, ISPOR Slovakia Regional Chapter and Faculty of Pharmacy, Comenius University and Faculty of Medicine, Slovak Medical University, Bratislava, Slovakia; Dragana Atanasijevic, MSc, Coordinator for Quality Component DILS/SHPAF Projects, Ministry of Health Serbia, Belgrade, Serbia

Speaker: Paul Radu, MD, PhD, Market Access Manager, Roche Romania, Bucharest, Romania
18:00 - 19:00
POSTER AUTHOR DISCUSSION HOUR – SESSION IV
19:30 - 23:00

An evening at Wasserwerk (an historic converted waterworks!).  Evening features, buffet dinner & open bar (wine, beer and soft drinks), DJ and dancing!

Separate registration required. Register now as registration during the Congress is subject to availability.